Clinical Trials Sponsored by Medeor Therapeutics, Inc.

Total 3049 results

Sorrento Therapeutics, Inc.

Enrolling by invitation

Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy

Long-term Follow-up

United States
Karyopharm Therapeutics Inc

Withdrawn

Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19

Coronavirus Infection
Karyopharm Therapeutics Inc

Withdrawn

Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients

Diabetic Foot Ulcers

New Zealand
Karyopharm Therapeutics Inc

Terminated

Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults

Healthy

Australia
Xalud Therapeutics, Inc.

Completed

Efficacy and Safety of XT-150 in Osteoarthritis of the Knee

Osteoarthritis, Knee

Australia, United States
Aldeyra Therapeutics, Inc.

Completed

A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

Atopic Asthma

Canada
Cidara Therapeutics Inc.

Completed

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis (ReSTORE)

Mycoses | Candidemia | Fungal Infection | Invasive Candidiases

United States, Israel, Spain, Korea, Republic of, Taiwan, Singapore, Thailand, Australia, China, Turkey, Belgium, Germany, France, Argentina, Bulgaria, Colombia, Greece, Italy
Cardiol Therapeutics Inc.

Terminated

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors

Cardiovascular Diseases | COVID-19 | Cardiovascular Risk Factor

United States, Brazil, Mexico
Applied Therapeutics, Inc.

Active, not recruiting

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

Diabetic Cardiomyopathies

United States, France, Spain, Australia, Canada, United Kingdom, Germany, Czechia, Hong Kong, Poland
Abeona Therapeutics, Inc

Completed

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa

United States
TG Therapeutics, Inc.

Completed

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

B-cell Lymphoma | Marginal Zone Lymphoma | Primary Central Nervous System Lymphoma | Waldenstrom's Macroglobulinemia | Non-Hodgkins Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Antios Therapeutics, Inc

Terminated

Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects

Chronic Hepatitis b

United States
Samus Therapeutics, Inc.

Terminated

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera Myelofibrosis (Post-PV MF) | Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

United States
Samus Therapeutics, Inc.

Withdrawn

Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)
Lisata Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI)

Critical Limb Ischemia | Thromboangiitis Obliterans | Buerger Disease | Atherosclerosis Obliterans

Japan
Kymera Therapeutics, Inc.

Completed

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

Atopic Dermatitis | Healthy Volunteer | Hidradenitis Suppurativa

United States
TG Therapeutics, Inc.

Completed

Ublituximab + Ibrutinib in Select B-cell Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia

United States
Biosplice Therapeutics, Inc.

Active, not recruiting

A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

United States
InteKrin Therapeutics, Inc.

Completed

A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus

Diabetes Mellitus, Type II

United States
Axsome Therapeutics, Inc.

Completed

Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP)

Obstructive Sleep Apnea | Excessive Daytime Sleepiness | Impaired Cognitive Function

Spain, United States, Canada, Netherlands, Italy, United Kingdom
Regulus Therapeutics Inc.

Completed

A Study of RGLS8429 in Healthy Volunteers

Healthy Volunteers

United States
Axsome Therapeutics, Inc.

Completed

A Trial of AXS-05 in Patients With Major Depressive Disorder (GEMINI)

Depression | Major Depressive Disorder

United States
Pipeline Therapeutics, Inc.

Completed

PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers

Multiple Sclerosis

United Kingdom
Protagonist Therapeutics, Inc.

Completed

Pharmacokinetics of PN-232 in Healthy Volunteers

Healthy Subjects

Australia
Gemini Therapeutics, Inc.

Terminated

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration

Macular Degeneration | Retinal Degeneration | Geographic Atrophy | Dry Age-related Macular Degeneration | Retinal Disease

United States
LENZ Therapeutics, Inc

Completed

A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

Presbyopia

United States
Ashvattha Therapeutics, Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

Australia
CymaBay Therapeutics, Inc.

Terminated

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

NASH - Nonalcoholic Steatohepatitis

United States
Jounce Therapeutics, Inc.

Completed

Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (EMERGE)

Cancer

United States, Canada
Eureka Therapeutics Inc.

Terminated

Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma (ET-109)

Hepatocellular Carcinoma | Liver Neoplasm | Liver Cancer | Metastatic Liver Cancer

United States
Stemline Therapeutics, Inc.

Completed

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

Metastatic Breast Cancer

Netherlands, Belgium
Seres Therapeutics, Inc.

Terminated

A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis (ECO-RESET)

Ulcerative Colitis

United States, Canada
NFlection Therapeutics, Inc.

Completed

NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

Neurofibromatosis 1 | Cutaneous Neurofibroma

United States
Akero Therapeutics, Inc

Completed

A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

NASH - Nonalcoholic Steatohepatitis

United States, Puerto Rico
Fortis Therapeutics, Inc.

Completed

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission

United States
TG Therapeutics, Inc.

Terminated

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma

United States, Poland, Australia, Italy, United Kingdom, Israel, Korea, Republic of, Slovakia, Spain
CymaBay Therapeutics, Inc.

Completed

Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)

Primary Biliary Cirrhosis

United States, Germany, United Kingdom, Canada
Axsome Therapeutics, Inc.

Completed

Mechanistic Evaluation of Response in TRD (MERIT) (MERIT)

Major Depressive Disorder | Treatment Resistant Depression

United States
Arcturus Therapeutics, Inc.

Terminated

A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

Covid19 | Corona Virus Infection | SARS-CoV Infection

United States, Singapore
Arcturus Therapeutics, Inc.

Terminated

Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021

SARS-CoV-2

Singapore
Antios Therapeutics, Inc

Terminated

A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection

Chronic Hepatitis b

Moldova, Republic of, Ukraine
Abeona Therapeutics, Inc

Terminated

A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

Mucopolysaccharidosis III-B

United States, Germany, France
Panbela Therapeutics, Inc.

Completed

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Stage IV Pancreatic Cancer

United States, Australia
Vyne Therapeutics Inc.

Completed

VPD-737 for Treatment of Chronic Pruritus

Chronic Pruritus

United States
Solace Therapeutics, Inc.

Terminated

Vesair Clinical Trial (VAPOR)

Stress Urinary Incontinence

United States
AnHeart Therapeutics Inc.

Completed

A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin

Solid Tumor

China
Carmot Therapeutics, Inc.

Completed

A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose.

Diabetes

United States
Cara Therapeutics, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

Uremic Pruritus

United States
Eirion Therapeutics Inc.

Completed

ET-01 in Subjects With Lateral Canthal Lines

Lateral Canthal Lines | Crow's Feet

United States
Cara Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (KARE)

Pruritus | Atopic Dermatitis

United States, Canada

Clinical Trials Sponsored by Medeor Therapeutics, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations